DelveInsight’s, “Allergic Rhinitis Pipeline Insight 2025” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Allergic Rhinitis pipeline landscape. It covers the Allergic Rhinitis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Allergic Rhinitis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Allergic Rhinitis Pipeline? Click here to explore the therapies and trials making headlines @ Allergic Rhinitis Pipeline Outlook Report
Key Takeaways from the Allergic Rhinitis Pipeline Report
- On 16 September 2025, Advagene Biopharma Co. Ltd. announced a study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo. Subjects will be randomized at 3:1 ratios in each of 3 cohorts to receive AD17002 or placebo.
- DelveInsight’s Allergic Rhinitis Pipeline report depicts a robust space with 35+ active players working to develop 35+ pipeline therapies for Allergic Rhinitis treatment.
- The leading Allergic Rhinitis Companies such as Poxel, Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Array Biopharma, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma and others.
- Promising Allergic Rhinitis Therapies such as GSK256066, Azelastine Hydrochloride, Fluticasone Furoate Nasal Spray, Stapokibart Injection, CM310, MK0476, Loratadine, FEX60/PE10 and others.
Want to know which companies are leading innovation in Allergic Rhinitis? Dive into the full pipeline insights @ Allergic Rhinitis Clinical Trials Assessment
The Allergic Rhinitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Allergic Rhinitis Pipeline Report also highlights the unmet needs with respect to the Allergic Rhinitis.
Allergic Rhinitis Overview
Allergic rhinitis (AR) is an atopic disease presenting with symptoms of sneezing, nasal congestion, clear rhinorrhea, and nasal pruritis. It is an IgE-mediated immune response that is against inhaled antigens in the immediate phase, with a subsequent leukotriene-mediated late phase. It affects one in six individuals and is associated with significant morbidity, loss of productivity, and healthcare costs. Historically, AR was thought to be a disease process of the nasal airway alone. Still, the development of the unified airway theory has classified AR as a component of systemic allergic response, with other associated conditions, such as asthma and atopic dermatitis, sharing an underlying systemic pathology.
Allergic Rhinitis Emerging Drugs
- REGN5713-5714-5715: Regeneron Pharmaceuticals
REGN5713-5714-5715 is a cocktail of three Bet v1 monoclonal antibodies. Regeneron Pharmaceuticals is investigating REGN5713-5714-5715 as intravenous injections in Phase III clinical studies for the treatment of allergic rhinitis and conjunctivitis.
- MM09-MG01: Immunotek
Inmunotek is developing a subcutaneously administered immunotherapy product MM 09, containing biological extracts of house dust mite, designated as M 601 (MM09-MG01). A Phase III Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and allergic rhinitis/rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and grass pollen has been initiated.
If you’re tracking ongoing Allergic Rhinitis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Allergic Rhinitis Treatment Drugs
The Allergic Rhinitis Pipeline report provides insights into:-
- The report provides detailed insights about companies that are developing therapies for the treatment of Allergic Rhinitis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Allergic Rhinitis Treatment.
- Allergic Rhinitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Allergic Rhinitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Allergic Rhinitis market.
Allergic Rhinitis Companies
Poxel, Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Array Biopharma, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma and others.
Allergic Rhinitis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Allergic Rhinitis Products have been categorized under various Molecule types such as,
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
From emerging drug candidates to competitive intelligence, the Allergic Rhinitis Pipeline Report covers it all – check it out now @ Allergic Rhinitis Market Drivers and Barriers, and Future Perspectives
Scope of the Allergic Rhinitis Pipeline Report
- Coverage- Global
- Allergic Rhinitis Companies- Poxel, Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Array Biopharma, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma and others.
- Allergic Rhinitis Therapies- GSK256066, Azelastine Hydrochloride, Fluticasone Furoate Nasal Spray, Stapokibart Injection, CM310, MK0476, Loratadine, FEX60/PE10 and others.
- Allergic Rhinitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Allergic Rhinitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research – discover what’s next for the Allergic Rhinitis Treatment landscape in this detailed analysis @ Allergic Rhinitis Emerging Drugs and Major Players
Table of Contents
- Introduction
- Executive Summary
- Allergic Rhinitis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- REGN5713-5714-5715: Regeneron Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- IRL201104: Revolo Biotherapeutics
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Drug profiles in the detailed report…..
- Inactive Products
- Allergic Rhinitis Key Companies
- Allergic Rhinitis Key Products
- Allergic Rhinitis- Unmet Needs
- Allergic Rhinitis- Market Drivers and Barriers
- Allergic Rhinitis- Future Perspectives and Conclusion
- Allergic Rhinitis Analyst Views
- Allergic Rhinitis Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/allergic-rhinitis-pipeline-insight